Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Over the past several years, improved disease understanding and advances in therapeutic options have led to a substantial shift in approach to the management of Crohn’s disease (CD). Rather than focusing solely on symptom control, current treatment algorithms now emphasize early intervention and the achievement of full disease control, with an eye toward preventing disease progression, and avoiding bowel damage and disability. In addition, healthcare providers must also be equipped to identify appropriate disease measures for accurately gauging therapeutic success and select optimal treatment from what has become an expansive range of options spanning traditional agents to advanced targeted therapies.
Aline Charabaty, MD, AGAF, FACG
Associate Professor of Medicine
Johns Hopkins School of Medicine
Clinical Director, GI Division
Director, IBD Center
Sibley Memorial Hospital
Washington, District of Columbia
Edward V. Loftus, Jr., MD
Professor of Medicine
Co-Director, Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology and Hepatology
Mayo Clinic College of Medicine
Sultan Mahmood, MD (Chair)
Assistant Professor of Medicine
Co-Program Director, GI Fellowship Program
Jacobs School of Medicine and Biomedical Sciences
University at Buffalo
Buffalo, New York
This educational activity has been designed to meet the needs of gastroenterologists, gastroenterologists in training, surgeons, subspecialists including dieticians and psychologists, nurse practitioners, physician assistants, nurses, and other healthcare team members involved in or interested in the care of patients with CD.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of November 10, 2021 through November 10, 2022, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Physician Continuing Education
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Live Participation on November 10, 2021:
Integrity Continuing Education, Inc. designates this live program for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation from November 11, 2021 to November 10, 2022:
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or email@example.com.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Aline Charabaty, MD, AGAF, FACG
Consulting Fees: AbbVie, Janssen, Pfizer, Takeda
Edward V. Loftus, Jr., MD
Consulting Fees: AbbVie, Allergan, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Genentech, Gilead, Iterative Scopes, Janssen, Pfizer, Takeda
Contracted Research: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Janssen, Pfizer, Robarts Clinical Trials, Takeda, Theravance
Sultan Mahmood, MD has no real or apparent conflicts of interest to disclose.
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.